Fermentalg Records Record Revenue of 13.4 Million Euros in 2025, Up 17%

Record Sales and Diversified Business Segments in 2025

Fermentalg recorded unaudited revenues of 13.4 million euros in 2025, marking a 17% increase from 2024, according to the press release published on January 28, 2026. This new sales record exceeded the company's latest forecasts. The performance was impacted by a slower-than-expected start from major accounts due to cautious stock management in an uncertain macroeconomic environment and depressed fish oil prices. The diversification of commercial outlets was confirmed: 43% of the 2025 sales were made in segments other than dietary supplements, notably in infant nutrition and aquaculture, compared to 5% in 2024. Fermentalg, the sole European producer of algal-origin omega-3, has expanded its ?rigins™ range. For 2026, the group expects a strong acceleration in growth driven by continued development of lipid sales (?rigins™) and initial revenues from the natural colorants segment (Galdieria Blue™), with the ambition of reaching 20 million euros in revenue.

Significant Industrial Investment in 2025

The year 2025 was marked by a multi-million euro industrial investment led by Huvepharma, a European leader in precision fermentation and a strategic partner who became a reference shareholder of Fermentalg. These investments facilitated the start of Galdieria Blue™ production and the internalization of the algal oil refining step, unlocking commercial potential while optimizing cost price. The company estimates it has the industrial capacity to achieve up to 50 million euros in annual revenue in the coming years without significant additional investment in production. In 2025, growth was accompanied by a reduction in gross financial debt of more than 6 million euros, including 4 million euros of convertible bonds repaid in cash. To support the acceleration of its growth and achieve operational break-even, Fermentalg is in promising talks with Huvepharma to obtain financial support of up to 4 million euros in the form of convertible bonds. The company expects a substantial improvement in results in 2026, although it will not achieve a positive EBITDA before the second half of 2026.

Launch of New Product Lines and Strategic Developments

Fermentalg launched the EPA/DHA ?rigins™ range, an algal oil rich in omega-3 with a composition and nutritional contributions equivalent to fish oils. This new range has generated significant interest among dairy industry players, and the first volume sales are expected in 2026 in a major market segment currently not served by Fermentalg. The natural blue colorant Galdieria Blue™ has been approved by the U.S. Food and Drug Administration (FDA). Production of the first industrial batches began in early 2026, allowing the start of qualification processes with global leaders in functional beverages. Fermentalg and its partner Givaudan are targeting significant revenues as early as 2026 and are preparing the terms of a long-term contractual commitment for the commercialization of the product under the Everzure™ Galdieria brand. In early 2026, Fermentalg and other shareholders of CarbonWorks (SUEZ, BNP Paribas, Bpifrance, Demeter, and Naco) defined the basis of an agreement strengthening the ties between the two companies. Fermentalg will hold the majority of the capital of CarbonWorks, whose financing is secured until 2028. A new website, including a Chinese version, was launched at the beginning of 2026.